Objective: To explore the regulatory effect of TRIP13 on the proliferation and apoptosis of B-cell lymphoma cells and its possible molecular mechanism by knocking down/overexpressing TRIP13 on the cell lines Granta-519 and JVM-2.
Methods: Lentiviral transfection technology was used to construct Granta-519 and JVM-2 cells with knocked down or overexpressed TRIP13 and their control cells. The efficiency of transfection was determined by fluorescence microscopy. The efficiency of knockdown and overexpression was evaluated by real-time quantitative PCR and Western blot. The proliferation was detected by CCK-8 assay. The apoptosis was detected by the Annexin V-APC single staining. The cell cycle was detected by the PI staining. The expression levels of P53, MDM4, and BCL-2 were evaluated by Western blot.
Results: After TRIP13 was knocked down, the proliferation ability of Granta-519 and JVM-2 cells was significantly reduced, and the apoptosis rate significantly increased. After TRIP13 was overexpressed, the proliferation ability of Granta-519 and JVM-2 cells was significantly enhanced, and the apoptosis was significantly reduced. After TRIP13 was knocked down, Granta-519 cells had obvious G phase arrest, and JVM-2 cells had obvious G and G/M phase arrest. After TRIP13 was knocked down in Granta-519 cells, the expression of BCL-2 protein decreased, while MDM4 protein increased. After TRIP13 was overexpressed, the expression of MDM4 protein decreased. After TRIP13 was overexpressed in JVM-2 cells, the expression of BCL-2 protein increased.
Conclusion: TRIP13 promotes the proliferation of B-cell lymphoma cells, inhibits their apoptosis, and affects their proliferation and apoptosis by participating in the regulation of the cell cycle. TRIP13 promotes the expression of BCL-2 proteins and inhibits the expression of MDM4 protein in B-cell lymphoma cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2021.05.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CircBCAR3 sponges miR-27a-3p and mediates ferroptosis in human B-prolymphocytic leukaemia cells via SLC7A11.
Cell Mol Biol (Noisy-le-grand)
November 2023
Department of Hematopathology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
B-lymphocytic leukaemia is one of the most commonly diagnosed blood malignancies, and our knowledge of B-prolymphocytic leukaemia remained barely comprehensive. CircRNAs and miRNAs were identified of important regulatory roles in tumours. This study focused on the possibly existing interaction of circBCAR3 and miR-27a-3p, and downstream molecules thereafter in B-prolymphocytic leukaemia cells.
View Article and Find Full Text PDFThe Effects of Adiponectin on the Behavior of B-Cell Leukemia Cells: Insights from an In Vitro Study.
Biomedicines
September 2023
Dipartimento di Scienze e Tecnologie Ambientali, Biologiche, Farmaceutiche, Università della Campania "Luigi Vanvitelli", Via A. Vivaldi, 81100 Caserta, Italy.
Article Synopsis
- A study investigated AdipoRon, an adiponectin agonist, on JVM-2 lymphoblast cells to assess its impact on cell viability, growth, invasiveness, and molecular signaling.
- Results showed that while AdipoRon reduced cell viability and increased colony formation, it also enhanced invasiveness and suggested a potential role in promoting aggressive behaviors of B lymphoma cells, indicating the need for further research on its mechanisms and implications in cancer progression.
[Regulation of TRIP13 on Proliferation and Apoptosis of B-Cell Lymphoma Cells and Its Mechanism].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
October 2021
Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China E-mail:
Objective: To explore the regulatory effect of TRIP13 on the proliferation and apoptosis of B-cell lymphoma cells and its possible molecular mechanism by knocking down/overexpressing TRIP13 on the cell lines Granta-519 and JVM-2.
Methods: Lentiviral transfection technology was used to construct Granta-519 and JVM-2 cells with knocked down or overexpressed TRIP13 and their control cells. The efficiency of transfection was determined by fluorescence microscopy.
Overexpression of lncRNA GATA6-AS inhibits cancer cell proliferation in mantle cell lymphoma by downregulating GLUT1.
Oncol Lett
September 2019
Nursing College of Beihua University, Jilin City, Jilin 132013, P.R. China.
Long non-coding RNA GATA6 antisense RNA 1 (lncRNA GATA6-AS) is a recently identified lncRNA that is involved in endothelial-mesenchymal transition. The present study aimed to investigate the involvement of GATA6-AS in the progression of mantle cell lymphoma (MCL). It was found that plasma lncRNA GATA6-AS expression level was downregulated in patients with MCL, compared with that in healthy controls.
View Article and Find Full Text PDFPromising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma.
J Cancer Res Clin Oncol
April 2018
Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China.
Purpose: We researched into the effect and mechanism of AC0010, a novel BTK inhibitor, in MCL, and compared its efficacy and safety with Ibrutinib to develop a preclinical study for the future therapy of MCL.
Methods: MTS assay was used to detect the growth inhibition caused by AC0010 and Ibrutinib, respectively, in MCL cell lines (Jeko-1 and JVM-2), primary MCL cells, and normal peripheral lymphocytes. Apoptosis of Jeko-1 and JVM-2 after exposure into AC0010 and Ibrutinib was conducted by flow cytometry; the expression of apoptosis-related proteins was checked by Western blot.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!